Ferrer’s constant commitment to innovation means that a strategy of alliances and collaboration with public research bodies and prestigious biotech companies is essential.
ADVANCE (CAT) is a consortium led by the University of Barcelona and Ferrer, made up of by eighteen reference health organizations. As such, it integrates the main biomedical research and teaching centers in Catalonia, as well as public bodies , private foundations and Catalan healthcare companies.
The aim of the ADVANCECAT project is to create an organizational structure to accelerate the development of new advanced therapy medicines, for better management of resources in order to obtain the maximum benefit in the Catalan health system. The creation of a new collaborative network avoids possible overlaps between the various participating institutions and allows them to work in a coordinated way. The main areas of focus are cell therapy, gene therapy and tissue engineering.
The key success of the project has been the integration of organizations in the field of biomedical research, its clinical application and its industrial production. Together, strengths and opportunities have been identified to meet the challenges presented in the field of advanced therapies, enhance research and accelerate the development of new products with a qualitative impact on health systems. These serve as a basis for promoting new economic opportunities in Catalonia. Among the most important results of the whole project are the 8 Phase I and II clinical trials of advanced therapies that have been or are being carried out, in which 171 patients have been treated. In addition, 32 articles have been published in international journals and 3 are pending approval.
Organizations that form part of the ADVANCECAT project:
University of Barcelona (leader), Ferrer (co-leader), Banc de Sang i Teixits, Barcelona Macula Foundation, Bioibérica SA, Butler Scientifics SL, Centre de Medicina Regenerativa de Barcelona, Fundació Bosch i Gimpera, FC Barcelona Universitas - Muscletech Network, Fundació Hospital Universitari Vall d’Hebron - Institut de Recerca, Fundació Institut de Bioenginyeria de Catalunya, Fundació Institut d’Investigacions en Ciències de la Salut Germans Trias i Pujol, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Fundació Leitat - Muscletech Network, Institut d’Investigació Biomèdica August Pi i Sunyer, Institut d’Investigació Biomèdica de Bellvitge, Tecnologia Regenerativa Qrem, i Universitat Autònoma de Barcelona.
The project is integrated into the NEXTHEALTH community, and has been co-financed by the European Union within the framework of the European Regional Development Fund (ERDF) Catalonia 2014-2020 operational program.
The Spanish National Centre for Cardiovascular Research (CNIC) is a public institution connected to the Carlos III Health Institute, which, under the leadership of its General Director, the distinguished cardiologist Dr. Valentin Fuster, has become a leading international research organization. Its mission is to undertake research into cardiovascular diseases with the aim of translating its expertise into clinical excellence, in order to prioritise prevention and promote health.
The CNIC and Ferrer, with the backing of the World Heart Federation, has developed the world’s first polypill for the secondary prevention of cardiovascular accidents in patients already undergoing treatment. It presents an important galenic innovation which ensures the stability and non-interaction of its three components.
It represents a significant advance in the worldwide treatment of cardiovascular diseases. The objective is to reduce the risk of suffering a second cardiovascular event. It provides medical professionals with a new therapeutic alternative, of proven efficacy, to improve patient adherence. Furthermore, ensuring affordable patient access to the treatment is one of the pillars of the CNIC-Ferrer project.
Alexza is a pharmaceutical company based in the United States dedicated to the research, development and commercialization of novel proprietary products for the treatment of acute and intermittent conditions.
The company's innovative products are based on the proprietary Staccato® system, an inhaler which vaporizes excipient-free drugs, achieving pharmacokinetic properties similar to intravenous administration and rapid systemic effects.
Adasuve® is designed for the rapid treatment of mild to moderate agitation in adults with schizophrenia or bipolar disorder, by combining the Staccato system with loxapine, an antipsychotic drug currently available in various formulations.